ArticleBMC infectious diseases2025
Characterization of urinary tract infections among females at a tertiary hospital in Malawi: a retrospective study.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Distribution and antibiotic resistance profiles of uropathogens at Madan Bhandari Hospital, Nepal: Focus on multidrug and extensively drug-resistant strains.IJID regions · 2026Article
- Distribution and antimicrobial resistance of uropathogens: a 6-year retrospective single-center study (2019-2024).BMC infectious diseases · 2026Article
- Prevalence of extended spectrum beta lactamase and molecular detection of blaInternational microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
- Utilisation of antibiotics in the management of urinary tract infections among women of reproductive age at a district hospital in Ghana.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUrinary tract infections (UTIs) are among the most common infections in females, with many experiencing at least one episode in their lifetime. About 150 million cases of UTIs occur each year. Lately, the prognosis of UTIs has been poor, largely due to a rise in antimicrobial resistance among common uropathogens. The present study was conducted to describe UTIs in female clients at Zomba Central Hospital in Malawi.
methodsThis was a retrospective cross-sectional study where 340 records of women suffering from UTIs were evaluated. Records were analysed for demographic characteristics, the causative agent of UTIs and their antimicrobial susceptibility profile. Data were cleaned and analysed in Excel 2016.
resultsThe overall prevalence of UTIs was 48.53%, with age group 15-45 having a higher frequency (53.33%) than other age groups. The most frequently isolated bacteria were Escherichia coli (27.2%), Staphylococcus species (26.5%), Enterobacter species (19.2%), Citrobacter freundii (11.9%), Proteus species (6.0%), Enterococcus species, and Serratia marcescens (4.6%). Comparatively, meropenem and amikacin were effective against most pathogens showing average sensitivity rates of 51% and 56% respectively. Nevertheless, high levels of resistance to ampicillin (87%), ceftriaxone (77%) ciprofloxacin (70%), gentamicin (77%), and cefoxitin (64%) were observed.
conclusionUTIs remain a significant health concern among females at Zomba Central Hospital, particularly in the reproductive age group. The high prevalence of multidrug-resistant uropathogens, especially against commonly used antibiotics like ampicillin and ceftriaxone, underscores the urgent need for regular antimicrobial resistance surveillance and evidence-based antibiotic stewardship to guide effective treatment strategies. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.